2022-02-182022-02-182011-10Demirkaya, M. vd. (2011). "Time-dependent alterations in growth and bone health parameters evaluated at different posttreatment periods in pediatric oncology patients". Pediatric Hematology and Oncology, 28(7), 588-599.0888-00181521-0669https://doi.org/10.3109/08880018.2011.603819https://www.tandfonline.com/doi/full/10.3109/08880018.2011.603819http://hdl.handle.net/11452/24529Bone mineral density (BMD) and anthropometric measurements in pediatric cancer patients were evaluated and compared at early and late posttreatment periods. Sixty-six pediatric cancer patients who recovered completely following treatment longer than at least a 6-month period were included in the study. Patients were evaluated cross-sectionally and prospectively with regard to anthropometric measurements and BMD twice; the first being at a mean period of 2.62 +/- 1.44 years and the second of 6.55 +/- 1.71 years after the completion of treatment. Rates of osteoporosis and osteopenia at first or second evaluation were 25.8% and 39.4% or 10.6% and 19.7%, respectively. Mean BMD z-scores were (-1.26) +/- 1.12 [(-4.3)-2.0] and (-0.48) +/- 1.25 [(-3.30)-3.40] at first and second evaluations, respectively. BMD findings obtained at second evaluation revealed statistically significant recovery compared with those obtained at first evaluation (P = .001). BMD z-scores were significantly lower in patients who received, as opposed to those who did not receive, radiotherapy (RT) at both evaluations. Anthropometric parameters of patients such as height, weight, and body mass index (BMI) were increased at both evaluations compared with values obtained at diagnosis (P < .05). Height standard deviation score (SDS) decreased at first evaluation compared with that measured at diagnosis, whereas it increased at second evaluation. Conversely, weight SDS and BMI SDS increased (P < .05) at first evaluation compared with that measured at diagnosis, whereas they decreased at second evaluation. The authors conclude that early impairments in anthropometric measurements recover in the long term, whereas BMD is continually reduced in children who recovered from cancer.eninfo:eu-repo/semantics/closedAccessOncologyHematologyPediatricsAnthropometricBone mineral densityChildhood cancer survivorsAcute lymphoblastic-leukemiaLong-term survivorsMineral densityChildhood-cancerBody-compositionChildrenChemotherapyTherapyTurnoverPrednisoloneAnthropometryAntineoplastic combined chemotherapy protocolsBody heightBody mass indexBody weightBone densityBone developmentChildChild, preschoolCross-sectional studiesFemaleFollow-up studiesHumansInfantInfant, newbornMaleNeoplasm stagingNeoplasmsProspective studiesTime factorsTreatment outcomeArticle0002950848000052-s2.0-8005306906558859928721936621OncologyHematologyPediatricsAcute Lymphoblastic Leukemia; Bone Density; Photon AbsorptiometryCyclophosphamideDexamethasoneEtoposideEtoposide derivativeIfosfamideMethotrexatePrednisoloneVinca alkaloidAnthropometric parametersArticleBody heightBody massBody weightBone densityBone growthBone tumorCancer chemotherapyCancer patientCancer radiotherapyChildChildhood cancerFemaleGerm cell tumorHodgkin diseaseHumanLong term careLymphatic system tumorMajor clinical studyMaleNeoplasmNonhodgkin lymphomaOncologyOsteopeniaOsteoporosisPreschool childProspective studyRetinoblastomaScoring systemSoft tissue sarcomaSolid tumor